How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
NANODX via ACUITY STRATEGIC PARTNERS LLC
2026 · second_quarter · Q2
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Source: Senate LDA
Medical device development, reimbursement for point of care services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2026 · first_quarter · Q1
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2025 · fourth_quarter · Q4
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STUDENTS FOR LIFE OF AMERICA via ACUITY STRATEGIC PARTNERS LLC
2025 · fourth_quarter · RR
Clean water in American cities
Clean water in American cities
NANODX via ACUITY STRATEGIC PARTNERS LLC
2025 · third_quarter · Q3
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2025 · second_quarter · Q2
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2025 · first_quarter · Q1
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2024 · fourth_quarter · Q4
Medicare and Medicaid rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2024 · third_quarter · Q3
Medicare and Medicaid rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2024 · second_quarter · Q2
Medicare and Medicaid rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2024 · first_quarter · Q1
Medicare and Medicaid rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2023 · fourth_quarter · Q4
Medicare and Medicaid rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2023 · third_quarter · Q3
Medicare and Medicaid rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMICUS THERAPEUTICS, INC. via ACUITY STRATEGIC PARTNERS LLC
2023 · third_quarter · 3T
Medicare and Medicaid rare diseases
Medicare and Medicaid rare diseases
Medicare and Medicaid rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARATEK PHARMACEUTICALS via ACUITY STRATEGIC PARTNERS LLC
2023 · second_quarter · Q2
Medicare and Medicaid reimbursement
Medicare and Medicaid reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APELLIS PHARMACUETICALS via ACUITY STRATEGIC PARTNERS LLC
2023 · second_quarter · Q2
Medicare and Medicaid reimbursement
Medicare and Medicaid reimbursement
Medicare and Medicaid reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAYSHA GENE THERAPIES via ACUITY STRATEGIC PARTNERS LLC
2023 · second_quarter · Q2
Medicare and Medicaid reimbursement
Medicare and Medicaid reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMICUS THERAPEUTICS, INC. via ACUITY STRATEGIC PARTNERS LLC
2023 · second_quarter · Q2
Medicare and Medicaid rare diseases
Medicare and Medicaid rare diseases
Medicare and Medicaid rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2023 · second_quarter · Q2
Medicare and Medicaid rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARATEK PHARMACEUTICALS via ACUITY STRATEGIC PARTNERS LLC
2023 · first_quarter · Q1
Medicare and Medicaid reimbursement
Medicare and Medicaid reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APELLIS PHARMACUETICALS via ACUITY STRATEGIC PARTNERS LLC
2023 · first_quarter · Q1
Medicare and Medicaid reimbursement
Medicare and Medicaid reimbursement
Medicare and Medicaid reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAYSHA GENE THERAPIES via ACUITY STRATEGIC PARTNERS LLC
2023 · first_quarter · Q1
Medicare and Medicaid reimbursement
Medicare and Medicaid reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2023 · first_quarter · Q1
Medicare and Medicaid rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMICUS THERAPEUTICS, INC. via ACUITY STRATEGIC PARTNERS LLC
2023 · first_quarter · Q1
Medicare and Medicaid rare diseases
Medicare and Medicaid rare diseases
Medicare and Medicaid rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARATEK PHARMACEUTICALS via ACUITY STRATEGIC PARTNERS LLC
2022 · fourth_quarter · Q4
Rare Disease research and Medicaid/Medicare reimbursement
Rare Disease research and Medicaid/Medicare reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APELLIS PHARMACUETICALS via ACUITY STRATEGIC PARTNERS LLC
2022 · fourth_quarter · Q4
Medicare reimbursement , Cell and Gene therapy research
Medicare reimbursement , Cell and Gene therapy research
Medicare reimbursement , Cell and Gene therapy research
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAYSHA GENE THERAPIES via ACUITY STRATEGIC PARTNERS LLC
2022 · fourth_quarter · Q4
Medicare reimbursement, CURES 2.0,
Medicare reimbursement, CURES 2.0,
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2022 · fourth_quarter · Q4
Medical device development, reimbursement of point of care services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMICUS THERAPEUTICS, INC. via ACUITY STRATEGIC PARTNERS LLC
2022 · fourth_quarter · Q4
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARATEK PHARMACEUTICALS via ACUITY STRATEGIC PARTNERS LLC
2022 · third_quarter · Q3
Rare Disease research and Medicaid/Medicare reimbursement
Rare Disease research and Medicaid/Medicare reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APELLIS PHARMACUETICALS via ACUITY STRATEGIC PARTNERS LLC
2022 · third_quarter · Q3
Medicare reimbursement , Cell and Gene therapy research
Medicare reimbursement , Cell and Gene therapy research
Medicare reimbursement , Cell and Gene therapy research
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAYSHA GENE THERAPIES via ACUITY STRATEGIC PARTNERS LLC
2022 · third_quarter · Q3
Medicare reimbursement, CURES 2.0,
Medicare reimbursement, CURES 2.0,
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2022 · third_quarter · Q3
Medical device development, reimbursement of point of care services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMICUS THERAPEUTICS, INC. via ACUITY STRATEGIC PARTNERS LLC
2022 · third_quarter · Q3
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARATEK PHARMACEUTICALS via ACUITY STRATEGIC PARTNERS LLC
2022 · second_quarter · Q2
Rare Disease research and Medicaid/Medicare reimbursement
Rare Disease research and Medicaid/Medicare reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APELLIS PHARMACUETICALS via ACUITY STRATEGIC PARTNERS LLC
2022 · second_quarter · Q2
Medicare reimbursement , Cell and Gene therapy research
Medicare reimbursement , Cell and Gene therapy research
Medicare reimbursement , Cell and Gene therapy research
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAYSHA GENE THERAPIES via ACUITY STRATEGIC PARTNERS LLC
2022 · second_quarter · Q2
Medicare reimbursement, CURES 2.0,
Medicare reimbursement, CURES 2.0,
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2022 · second_quarter · Q2
Medical device development, reimbursement of point of care services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMICUS THERAPEUTICS, INC. via ACUITY STRATEGIC PARTNERS LLC
2022 · second_quarter · Q2
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARATEK PHARMACEUTICALS via ACUITY STRATEGIC PARTNERS LLC
2022 · first_quarter · 1A
Rare Disease research and Medicaid/Medicare reimbursement
Rare Disease research and Medicaid/Medicare reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APELLIS PHARMACUETICALS via ACUITY STRATEGIC PARTNERS LLC
2022 · first_quarter · Q1
Medicare reimbursement , Cell and Gene therapy research
Medicare reimbursement , Cell and Gene therapy research
Medicare reimbursement , Cell and Gene therapy research
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAYSHA GENE THERAPIES via ACUITY STRATEGIC PARTNERS LLC
2022 · first_quarter · Q1
Medicare reimbursement, CURES 2.0,
Medicare reimbursement, CURES 2.0,
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2022 · first_quarter · Q1
Medical device development, reimbursement of point of care services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMICUS THERAPEUTICS, INC. via ACUITY STRATEGIC PARTNERS LLC
2022 · first_quarter · Q1
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARATEK PHARMACEUTICALS via ACUITY STRATEGIC PARTNERS LLC
2022 · first_quarter · RR
Rare Disease research and Medicaid/Medicare reimbursement
Rare Disease research and Medicaid/Medicare reimbursement
TAYSHA GENE THERAPIES via ACUITY STRATEGIC PARTNERS LLC
2021 · fourth_quarter · Q4
Medicare reimbursement, CURES 2.0,
Medicare reimbursement, CURES 2.0,
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APELLIS PHARMACUETICALS via ACUITY STRATEGIC PARTNERS LLC
2021 · fourth_quarter · Q4
Medicare reimbursement , Cell and Gene therapy research
Medicare reimbursement , Cell and Gene therapy research
Medicare reimbursement , Cell and Gene therapy research
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2021 · fourth_quarter · Q4
Medical device development, reimbursement of point of care services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMICUS THERAPEUTICS, INC. via ACUITY STRATEGIC PARTNERS LLC
2021 · fourth_quarter · Q4
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APELLIS PHARMACUETICALS via ACUITY STRATEGIC PARTNERS LLC
2021 · third_quarter · Q3
Medicare reimbursement , Cell and Gene therapy research
Medicare reimbursement , Cell and Gene therapy research
Medicare reimbursement , Cell and Gene therapy research
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAYSHA GENE THERAPIES via ACUITY STRATEGIC PARTNERS LLC
2021 · third_quarter · Q3
Medicare reimbursement, CURES 2.0,
Medicare reimbursement, CURES 2.0,
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2021 · third_quarter · Q3
Medical device development, reimbursement of point of care services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMICUS THERAPEUTICS, INC. via ACUITY STRATEGIC PARTNERS LLC
2021 · third_quarter · Q3
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APELLIS PHARMACUETICALS via ACUITY STRATEGIC PARTNERS LLC
2021 · second_quarter · Q2
Medicare reimbursement , Cell and Gene therapy research
Medicare reimbursement , Cell and Gene therapy research
Medicare reimbursement , Cell and Gene therapy research
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAYSHA GENE THERAPIES via ACUITY STRATEGIC PARTNERS LLC
2021 · second_quarter · Q2
Medicare reimbursement, CURES 2.0,
Medicare reimbursement, CURES 2.0,
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2021 · second_quarter · Q2
Medical device development, reimbursement of point of care services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMICUS THERAPEUTICS, INC. via ACUITY STRATEGIC PARTNERS LLC
2021 · second_quarter · Q2
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APELLIS PHARMACUETICALS via ACUITY STRATEGIC PARTNERS LLC
2021 · first_quarter · Q1
Medicare reimbursement , Cell and Gene therapy research
Medicare reimbursement , Cell and Gene therapy research
Medicare reimbursement , Cell and Gene therapy research
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAYSHA GENE THERAPIES via ACUITY STRATEGIC PARTNERS LLC
2021 · first_quarter · Q1
Medicare reimbursement, CURES 2.0,
Medicare reimbursement, CURES 2.0,
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2021 · first_quarter · 1A
Medical device development, reimbursement of point of care services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMICUS THERAPEUTICS, INC. via ACUITY STRATEGIC PARTNERS LLC
2021 · first_quarter · Q1
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2021 · first_quarter · Q1
Medical device development, reimbursement of point of care services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2020 · fourth_quarter · Q4
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMICUS THERAPEUTICS, INC. via ACUITY STRATEGIC PARTNERS LLC
2020 · fourth_quarter · Q4
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
APELLIS PHARMACUETICALS via ACUITY STRATEGIC PARTNERS LLC
2020 · fourth_quarter · Q4
Medicare reimbursement , Cell and Gene therapy research
Medicare reimbursement , Cell and Gene therapy research
Medicare reimbursement , Cell and Gene therapy research
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAYSHA GENE THERAPIES via ACUITY STRATEGIC PARTNERS LLC
2020 · fourth_quarter · Q4
Medicare reimbursement, CURES 2.0,
Medicare reimbursement, CURES 2.0
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAYSHA GENE THERAPIES via ACUITY STRATEGIC PARTNERS LLC
2020 · fourth_quarter · RR
Medicare reimbursement, CURES 2.0,
Medicare reimbursement, CURES 2.0,
APELLIS PHARMACUETICALS via ACUITY STRATEGIC PARTNERS LLC
2020 · fourth_quarter · RR
Medicare reimbursement , Cell and Gene therapy research
Medicare reimbursement , Cell and Gene therapy research
Medicare reimbursement , Cell and Gene therapy research
NANODX via ACUITY STRATEGIC PARTNERS LLC
2020 · third_quarter · Q3
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMICUS THERAPEUTICS, INC. via ACUITY STRATEGIC PARTNERS LLC
2020 · third_quarter · Q3
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2020 · second_quarter · Q2
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMICUS THERAPEUTICS, INC. via ACUITY STRATEGIC PARTNERS LLC
2020 · second_quarter · Q2
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2020 · second_quarter · RR
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
AMICUS THERAPEUTICS, INC. via ACUITY STRATEGIC PARTNERS LLC
2020 · first_quarter · Q1
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMICUS THERAPEUTICS, INC. via ACUITY STRATEGIC PARTNERS LLC
2019 · fourth_quarter · Q4
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMICUS THERAPEUTICS, INC. via ACUITY STRATEGIC PARTNERS LLC
2019 · third_quarter · Q3
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMICUS THERAPEUTICS, INC. via ACUITY STRATEGIC PARTNERS LLC
2019 · third_quarter · RR
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care
Reimbursement for rare disease patient care